Diabetes & metabolism最新文献

{"title":"Glucagon like peptide-1 receptor agonists in type 1 diabetes","authors":"Chao Deng, Wenqi Fan, Xia Li","doi":"10.1016/j.diabet.2023.101487","DOIUrl":"10.1016/j.diabet.2023.101487","url":null,"abstract":"","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 6","pages":"Article 101487"},"PeriodicalIF":7.2,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54233176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of chronic emotions and psychosocial stress on glycemic control in patients with type 1 diabetes. Heterogeneity of glycemic responses, biological mechanisms, and personalized medical treatment","authors":"Sylvia Franc ,&nbsp;Samir Bensaid ,&nbsp;Pauline Schaepelynck ,&nbsp;Laurent Orlando ,&nbsp;Philippe Lopes ,&nbsp;Guillaume Charpentier","doi":"10.1016/j.diabet.2023.101486","DOIUrl":"10.1016/j.diabet.2023.101486","url":null,"abstract":"<div><p>Many studies have clearly established that chronic psychosocial stress may sustainably worsen glycemic control in patients with type 1 diabetes mellitus (T1DMM), thus promoting diabetes complications. Chronic psychosocial stress may be due to: <em>i</em>) the long-term accumulation of stressful life events that require readjustment on the part of the individual (loosing friends, changing schools), and/or <em>ii</em>) exposure to severe chronic stressors (persistent difficulties and adversities of life). Whatever the reason, many studies have clearly established a positive correlation between chronic psychosocial stress and HbA1c levels. However, a small fraction of patients is minimally affected or not affected at all by chronic psychosocial stress. Conversely, positive life events can substantially improve glycemic control. Recent evidence suggests the existence of subpopulations that differ in personality traits, neurohormonal regulatory responses, and food intake behavior (increased or decreased). Better characterization of the clinical and neurohormonal differences between these subpopulations may help develop personalized treatment strategies in the future. In the near future, psychotherapeutic support and automated insulin delivery (AID) could alleviate chronic stress, prevent worsening glycemic control, and ease the burden of diabetes.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 6","pages":"Article 101486"},"PeriodicalIF":7.2,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49687230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus","authors":"Alessandro Csermely ,&nbsp;Alessandro Mantovani ,&nbsp;Mario Luca Morieri ,&nbsp;Luisa Palmisano ,&nbsp;Maria Masulli ,&nbsp;Efisio Cossu ,&nbsp;Marco Giorgio Baroni ,&nbsp;Katia Bonomo ,&nbsp;Flavia Agata Cimini ,&nbsp;Gisella Cavallo ,&nbsp;Raffaella Buzzetti ,&nbsp;Carmen Mignogna ,&nbsp;Frida Leonetti ,&nbsp;Simonetta Bacci ,&nbsp;Roberto Trevisan ,&nbsp;Riccardo Maria Pollis ,&nbsp;Raffaella Aldigeri ,&nbsp;Alessandra Dei Cas ,&nbsp;Saula Vigili de Kreutzenberg ,&nbsp;Giovanni Targher","doi":"10.1016/j.diabet.2023.101477","DOIUrl":"10.1016/j.diabet.2023.101477","url":null,"abstract":"<div><h3>Aim</h3><p>We examined whether different insulin administration modalities, i.e., multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII by insulin pumps), are differently associated with the risk of having metabolic dysfunction-associated fatty liver disease (MAFLD), with or without coexisting significant liver fibrosis (assessed by validated non-invasive biomarkers), in adults with type 1 diabetes mellitus (T1DM).</p></div><div><h3>Methods</h3><p>We conducted a retrospective, multicenter, cross-sectional study involving 1,417 adult individuals with established T1DM treated with MDI or CSII. We calculated hepatic steatosis index (HSI) and fibrosis (FIB)-4 index for non-invasively detecting MAFLD (defined by HSI &gt;36), with or without coexisting significant fibrosis (defined by FIB-4 index ≥ 1.3 or &lt;1.3, respectively).</p></div><div><h3>Results</h3><p>Compared to the MDI group (<em>n</em> = 1,161), insulin-pump users (<em>n</em> = 256; 18.1%) were more likely to be younger (mean age: 40 <em>vs</em>. 48 years, <em>P</em> &lt; 0.001), had better glycemic control (mean hemoglobin A1c: 7.7%  vs. 7.9%, <em>P</em> = 0.025) and a markedly lower prevalence of MAFLD with coexisting significant fibrosis (2.7%  vs. 8.1%, <em>P</em> = 0.010), but a comparable prevalence of MAFLD without fibrosis. In multinomial logistic regression analysis, CSII therapy was associated with a ∼70%-lower risk of MAFLD with significant fibrosis (unadjusted odds ratio 0.32, 95% confidence interval 0.14–0.70; <em>P</em> = 0.004), but this association was no longer significant after adjustment for age, hemoglobin A1c and other potential confounders.</p></div><div><h3>Conclusion</h3><p>The lower prevalence of MAFLD with coexisting significant fibrosis we observed in adults with T1DM using CSII therapy, compared to those using MDI therapy, is primarily mediated by inter-group differences in age.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 6","pages":"Article 101477"},"PeriodicalIF":7.2,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10590648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excessive dietary sodium intake augments long-term risk of atrial fibrillation in older adults with hyperglycemia: A community-based prospective cohort study","authors":"Qin Zhang ,&nbsp;Yuqi Guo ,&nbsp;Mei Li ,&nbsp;Ruizhen Yang ,&nbsp;Yanli Yao ,&nbsp;Yingxin Zhao ,&nbsp;Haipeng Yin ,&nbsp;Hua Zhang ,&nbsp;Weike Liu ,&nbsp;Zhendong Liu","doi":"10.1016/j.diabet.2023.101475","DOIUrl":"10.1016/j.diabet.2023.101475","url":null,"abstract":"<div><h3>Aim</h3><p>Studies investigating the association between sodium intake and new-onset atrial fibrillation (AF) have come to controversial results. This study aimed to assess the effect of excessive sodium intake on new-onset AF in individuals with hyperglycemia.</p></div><div><h3>Methods</h3><p>Between April 2007 and November 2011, 2841 community-dwelling individuals aged 60 years and older were recruited from the Shandong area, China. Dietary sodium intake was estimated using 24-hour urine collection within seven consecutive days. Fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) were assessed. New-onset AF was diagnosed using ICD-10 with codes I48 (I48.0 – I48.9) during follow-up.</p></div><div><h3>Results</h3><p>The findings were that excessive sodium intake significantly and independently increased the risk of new-onset AF in older adults with hyperglycemia: hazard ratio (HR) 1.525 [95% confidence interval 1.147;2.029] adjusted P = 0.004. The risk of new-onset AF increased by 29.3% (HR 1.293 [1.108;1.509] adjusted P = 0.001) with a one-standard deviation increase in sodium intake. Excessive sodium intake synergistically interacted with hyperglycemia on the increased risk of new-onset AF (HR 1.599 [1.342;1.905] adjusted P &lt; 0.001 for FPG and HR 1.516 [1.271;1.808] adjusted P &lt; 0.001 for HbA1c).</p></div><div><h3>Conclusion</h3><p>Our findings indicate that excessive sodium intake independently enhances the risk of new-onset AF among patients with hyperglycemia. A sodium-restricted diet may perhaps result in a multiplier effect on reducing the risk of new-onset AF.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 5","pages":"Article 101475"},"PeriodicalIF":7.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10190471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycemic status during pregnancy according to fasting and post-load glucose values: The association with adverse pregnancy outcomes. An observational study","authors":"Emmanuel Cosson ,&nbsp;Sopio Tatulashvili ,&nbsp;Eric Vicaut ,&nbsp;Sara Pinto ,&nbsp;Meriem Sal ,&nbsp;Charlotte Nachtergaele ,&nbsp;Narimane Berkane ,&nbsp;Amélie Benbara ,&nbsp;Marion Fermaut ,&nbsp;Jean-Jacques Portal ,&nbsp;Lionel Carbillon ,&nbsp;Hélène Bihan","doi":"10.1016/j.diabet.2023.101469","DOIUrl":"10.1016/j.diabet.2023.101469","url":null,"abstract":"<div><h3>Aim</h3><p>Prognosis of treated hyperglycemia in pregnancy (HIP) may differ according to whether diagnosis following an oral glucose tolerance test (OGTT) is based on high fasting and/or high post-load glucose values.</p></div><div><h3>Methods</h3><p>From a multiethnic prospective study, we included 8,339 women screened for HIP after 22 weeks of gestation. We evaluated the risk of large-for-gestational-age (LGA) infant (primary endpoint) and other adverse pregnancy outcomes according to HIP status in four groups defined as follows: no HIP (<em>n</em> = 6,832, reference); isolated fasting HIP (<em>n</em> = 465), isolated post-load HIP (<em>n</em> = 646), and fasting and post-load HIP (<em>n</em> = 396).</p></div><div><h3>Results</h3><p>After adjusting for age, body mass index, ethnicity, smoking during pregnancy and parity, compared with no HIP, the adjusted odds ratios [95% confidence interval] for LGA infant were higher in the isolated fasting HIP (1.47 [1.11–1.96]) and fasting and post-load HIP (1.65 [1.23–2.21]) groups, but not in the isolated post-load HIP (1.13 [0.86–1.48]) group. The adjusted odds ratios for preterm delivery and neonatal intensive care unit were higher in the post-load HIP group (1.44 [1.03–2.03] and 1.28 [1.04–1.57], respectively), the fasting and post-load HIP group (1.81 [1.23–2.68] and 1.42 [1.10–1.81], respectively) but not in the isolated fasting HIP group (1.34 [0.90–2.00] and 1.20 [0.94–1.52], respectively).</p></div><div><h3>Conclusion</h3><p>Despite glucose-lowering care and adjustment for confounders, compared with no HIP, fasting HIP was associated with a higher rate of LGA infant, whereas post-load HIP was associated with higher preterm delivery and neonatal intensive care unit admission rates.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 5","pages":"Article 101469"},"PeriodicalIF":7.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10180202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies","authors":"André J. Scheen","doi":"10.1016/j.diabet.2023.101474","DOIUrl":"10.1016/j.diabet.2023.101474","url":null,"abstract":"<div><p>Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal disease. Some data suggested that glucagon-like peptide-1 receptor agonists (GLP-1RAs) exert a better protection against stroke than sodium-glucose cotransporter 2 inhibitors (SGLT2is). However, this conclusion was derived from indirect comparisons in absence of any head-to-head randomised controlled trial (RCT). The present comprehensive review compares the effects of SGLT2is versus GLP-1RAs on nonfatal and fatal/nonfatal strokes in network meta-analyses of RCTs (mostly cardiovascular outcome trials) versus placebo, on the one hand, and in real-life observational cohort studies, on the other hand. Whereas network meta-analyses of placebo-controlled RCTs confirm a slight but significant (in 11 out of 13 meta-analyses) higher incidence of stroke in patients treated with SGLT2is compared with those treated with GLP-1RAs, a large majority of retrospective observational cohort studies (19 out of 21) failed to find any significant difference in the risk of stroke between the two pharmacological classes. Available, yet limited, findings suggest that SGLT2is may be more efficacious against haemorrhagic than ischaemic strokes, in patients at risk for atrial fibrillation and in patients with chronic kidney disease.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 5","pages":"Article 101474"},"PeriodicalIF":7.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10251267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study","authors":"Zi-Yang Peng ,&nbsp;Yao-Tseng Wang ,&nbsp;Chin-Sung Chang ,&nbsp;Chih-Hsing Wu ,&nbsp;Huang-Tz Ou","doi":"10.1016/j.diabet.2023.101465","DOIUrl":"10.1016/j.diabet.2023.101465","url":null,"abstract":"<div><h3>Aims</h3><p>To retrospectively analyze the association of sodium-glucose cotransporter-2 inhibitors (SGLT2is) versus dipeptidyl peptidase-4 inhibitors (DPP4is) with a range of major and non-major fracture events, and explore heterogeneous treatment effect among high-risk patient subgroups.</p></div><div><h3>Methods</h3><p>Newly stable SGLT2i or DPP4i users in 2017 were identified in Taiwan's National Health Insurance Research Database and followed up until a fracture occurred, loss of follow-up, death, or December 31, 2018, whichever came first. Outcomes included composite major and non-major fractures and individual components in major fractures. Cox model and restricted mean survival time (RMST) analyses were utilized to assess the treatment effect on fractures.</p></div><div><h3>Results</h3><p>21,155 propensity-score-matched SGLT2i and DPP4i users were obtained. Over 2 years, the hazard ratio and RMST difference for major fracture with SGLT2i versus DPP4i use were 0.89 (95% CI, 0.80, 1.00) and 1.51 (-0.17, 3.17) days, respectively, and those for non-major fracture with SGLT2i versus DPP4i use were 0.89 (0.81, 0.98) and 2.44 (0.47, 4.37) days, respectively. A 180-day lag time analysis for fracture outcomes showed consistent results with primary findings. A SGLT2is-associated harmful effect on major fractures (but not on non-major fractures) was observed among female patients and those with a diabetes duration of ≥ 8 years, prior fractures, and established osteoporosis.</p></div><div><h3>Conclusion</h3><p>This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 5","pages":"Article 101465"},"PeriodicalIF":7.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10297211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between maternal autoimmune diseases and offspring risk of type 1 diabetes","authors":"Yu-Hsuan Pai ,&nbsp;Renin Chang ,&nbsp;Cheuk-Kwan Sun ,&nbsp;Wen-Bin Yeh","doi":"10.1016/j.diabet.2023.101467","DOIUrl":"10.1016/j.diabet.2023.101467","url":null,"abstract":"","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 5","pages":"Article 101467"},"PeriodicalIF":7.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10541186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum albumin and risk of incident diabetes and diabetic microvascular complications in the UK Biobank cohort","authors":"Yang-Wei Cai ,&nbsp;Hai-Feng Zhang ,&nbsp;Jing-Wei Gao ,&nbsp;Zhao-Xi Cai ,&nbsp;Jie-Wen Cai ,&nbsp;Qing-Yuan Gao ,&nbsp;Zhi-Teng Chen ,&nbsp;Guang-Hong Liao ,&nbsp;Chuan-Rui Zeng ,&nbsp;Nuo Chen ,&nbsp;Pin-Ming Liu ,&nbsp;Jing-Feng Wang ,&nbsp;Yang-Xin Chen","doi":"10.1016/j.diabet.2023.101472","DOIUrl":"10.1016/j.diabet.2023.101472","url":null,"abstract":"<div><h3>Aim</h3><p>To examine the associations between serum albumin and the incidences of diabetes and diabetic microvascular complications in participants of the UK Biobank cohort.</p></div><div><h3>Methods</h3><p>There were 398,146 participants without diabetes and 30,952 patients with diabetes from the UK Biobank cohort included in this study. Multivariate-adjusted Cox proportional hazard models were used to analyze the association of albumin with the incidences of diabetes and diabetic microvascular complications. Mendelian randomization (MR) analysis was used to determine the genetic relationships between serum albumin and diabetes.</p></div><div><h3>Results</h3><p>After a median 12.90 years follow-up, 14,710 participants developed incident diabetes (58.83 ± 7.52 years, 56.10% male). After multivariate adjustment, serum albumin was inversely associated with incident diabetes: hazard ratio (HR) [95% confidence interval] per 10 g/l increase 0.88 [0.82;0.94]. MR analyses suggested a potential genetic influence of serum albumin on diabetes in both the UK Biobank and the FinnGen consortium: odds ratios (ORs) [95% confidence interval per 1 g/l increase 0.99 [0.98;1.00] and 0.78 [0.67;0.92], respectively. In patients with diabetes, higher serum albumin levels were significantly associated with lower risk for diabetic microvascular complications. Specifically, per 10 g/l increase in serum albumin, the HRs for diabetic nephropathy, ophthalmopathy, and neuropathy were 0.42 [0.30;0.58], 0.61 [0.52;0.72], and 0.67 [0.51;0.88], respectively.</p></div><div><h3>Conclusion</h3><p>In this large prospective study, serum levels of albumin were inversely associated with the incidences of diabetes and diabetic microvascular complications. These findings underscore the importance of maintaining optimal nutrient status in reducing the risk of diabetes and its complications.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 5","pages":"Article 101472"},"PeriodicalIF":7.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10251265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperglycemia-related anxiety during competition in an elite athlete with type 1 diabetes: A case report","authors":"Alexandra Katz ,&nbsp;Aidan Shulkin ,&nbsp;Meryem K. Talbo ,&nbsp;Asmaa Housni ,&nbsp;Jane Yardley ,&nbsp;Anne-Sophie Brazeau ,&nbsp;Rémi Rabasa-Lhoret","doi":"10.1016/j.diabet.2023.101476","DOIUrl":"10.1016/j.diabet.2023.101476","url":null,"abstract":"<div><h3>Aim</h3><p>Managing blood glucose (BG) levels during intense physical activity is challenging for elite athletes with type 1 diabetes (T1D), as it can lead to unpredictable hyper- or hypoglycemia, which can affect performance. This case study presents an 18-year-old male hockey goalie with hyperglycemia-related anxiety during competition and its impact on his T1D management.</p></div><div><h3>Methods</h3><p>Mixed-methods approach, incorporating qualitative data from an unstructured interview and responses from the <em>Hyperglycemia Avoidance Scale</em> along with quantitative data retrieved from Diasend and laboratory results.</p></div><div><h3>Results</h3><p>The athlete experiences physical and cognitive symptoms during hyperglycemia, affecting his performance. Hyperglycemia-related anxiety influences insulin dosage adjustments and eating habits on game days. Glycemic variability analysis reveals lower BG levels during game time.</p></div><div><h3>Conclusion</h3><p>Hyperglycemia-related anxiety leads to modified therapeutic and lifestyle regimens on competition day. Tailored treatment programs are needed for elite athletes with T1D and hyperglycemia-related anxiety.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"49 5","pages":"Article 101476"},"PeriodicalIF":7.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10251672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}